Podcast

The Role of Race in Health Care Delivery in IBD

Launch Date
01/25/2021
Credit Amount
0.00 Expired
Credit Expires
02/25/2022

Faculty

Miguel Regueiro, MD
Moderator
Chief, Digestive Disease Institute
Professor in the Department of Medicine
Cleveland Clinic Lerner College of Medicine of Case Western Reserve University
Cleveland, OH
Miguel Regueiro, MD
Moderator

Miguel Regueiro earned his bachelor’s degree at the University of Pennsylvania, his medical degree at Drexel (Hahnemann) University and completed his internal medicine internship, residency, and clinical and research fellowship training in gastroenterology at Harvard Medical School’s Beth Israel Hospital.

Dr. Regueiro was Professor of Medicine and Clinical and Translational Science at the University of Pittsburgh School of Medicine from 2000 to 2018. There he served as the IBD Clinical Medical Director, Senior Medical Lead of Specialty Medical Homes, was Professor with Tenure, and honored as the UPMC Endowed Chair for Patient Centered Care in Inflammatory Bowel Diseases.

Dr. Regueiro is currently the Chair of the Department of Gastroenterology and Hepatology and Chair of the Digestive Disease and Surgery Institute at Cleveland Clinic in Ohio. He serves as Medical Co- Chair of Digestive Disease and Surgical Institute Research Governance committee and is Professor of Medicine at the Lerner College of Medicine, Cleveland Clinic.

Dr. Regueiro’s main clinical and research interest is Inflammatory Bowel Diseases with a focus on the natural course of these diseases and postoperative prevention of Crohn’s disease. Recently, he has been involved in transformative medicine initiatives and developing new models of healthcare, including the first-of-its kind specialty medical home for IBD. Dr. Regueiro is investigating alternative models of care in population-based health that integrates patients, payers, providers, pharmaceutical industry, and other facets of healthcare delivery around these novel programs.

Kofi Clarke, MD, FACP, FRCP (London), AGAF
Professor and Chief Division of Gastroenterology and Hepatology Penn State Hershey College of Medicine Penn State Milton S. Hershey Medical Center Hershey, PA
Kofi Clarke, MD, FACP, FRCP (London), AGAF

Dr. Clarke is a Professor of Medicine and Chief of the Division of Gastroenterology and Hepatology at Penn State Hershey College of Medicine. He previously served as Division Chief of Gastroenterology, Hepatology and Nutrition at Allegheny Health Network in Pittsburgh, PA.

He completed fellowship training in Gastroenterology, Hepatology and Nutrition at the University of Pittsburgh Medical Center; postgraduate training in Medicine and Gastroenterology with certification by the Royal College of Physicians of London; as well as Research Fellowship at Michigan State University. In addition, Dr. Clarke holds Certificates for Leadership Development for Physicians in Academic Health Centers from the Harvard School of Public Health and Excellence in Academic Medicine Program from the Penn State Leadership Academy.

His clinical and research interests are in luminal bowel disease, primarily inflammatory bowel disease (IBD) with a secondary interest in celiac disease. He also has an interest in graduate medical education.

He has published several peer-reviewed manuscripts, multiple abstracts, a book chapter, and is the site Principal Investigator of several multicenter clinical trials at Penn State Health Division of Gastroenterology and Hepatology. He has also been an invited speaker at several meetings on IBD and is a reviewer for several gastroenterology and medicine journals.

Dr. Clarke is a member of the American Gastroenterological Association, American College of Gastroenterology, Crohn’s and Colitis Foundation, and American College of Physicians as well as a fellow of the Royal College of Physicians of London.

Explore By Section
Statement of Need Learning Objectives Financial Support Target Audience Credit Information Disclosure Declaration Additional Formats

Statement of Need

Although IBD is more common in non-Hispanic Whites compared to other racial groups, there is a disproportionately higher ratio of hospitalizations, surgery, and IBD-related mortality among non-Hispanic African Americans compared with other racial groups. This fact, in addition to the rising prevalence of IBD in North America and the estimate that 54% of the U.S. population will be comprised of minority populations by 2050, underscores the need for high-quality treatment available to racial and ethnic minority groups.

In this CMEOCast podcast, expert faculty discuss variations in IBD presentation in different racial groups, disparities in health care use, and approaches to mitigate inequality.

Learning Objectives

At the end of this CME/CE activity, participants should be able to initiate multidisciplinary collaboration to provide medically underserved children, adolescents, and adults with IBD with guideline-recommended care.

Financial Support

Supported by educational grants from Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC, and Takeda Pharmaceuticals U.S.A., Inc.

Target Audience

Physicians, nurse practitioners, PAs, nurses, and pharmacists.

Credit Information

Physicians (ACCME) 1.0

CME Outfitters, LLC, designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Pharmacists/Pharmacy Tech (ACPE) 1.0

This application-based activity is approved for 1.0 contact hour (0.10 CEUs) of continuing pharmacy credit.

ABIM MOC 1.0

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.0 medical knowledge MOC point in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Royal College MOC

Through an agreement between the Accreditation Council for Continuing Medical Education and the Royal College of Physicians and Surgeons of Canada, medical practitioners participating in the Royal College MOC Program may record completion of accredited activities registered under the ACCME’s “CME in Support of MOC” program in Section 3 of the Royal College’s MOC Program.

MIPS Improvement Activity

Completion of this accredited CME activity meets the expectations of an Accredited Safety or Quality Improvement Program (IA_PSPA_28) for the Merit-based Incentive Payment Program (MIPS). Clinicians should submit their improvement activities by attestation via the CMS Quality Payment Program website.

Disclosure Declaration

It is the policy of CME Outfitters, LLC, to ensure independence, balance, objectivity, and scientific rigor and integrity in all of their CE activities. Faculty must disclose to the participants any relationships with commercial companies whose products or devices may be mentioned in faculty presentations, or with the commercial supporter of this CE activity. CME Outfitters, LLC, has evaluated, identified, and attempted to resolve any potential conflicts of interest through a rigorous content validation procedure, use of evidence-based data/research, and a multidisciplinary peer review process. The following information is for participant information only. It is not assumed that these relationships will have a negative impact on the presentations.

Dr. Regueiro reports that he receives research support from AbbVie Inc.; Janssen Pharmaceuticals, Inc.; and Takeda Pharmaceuticals U.S.A., Inc. He receives unrestricted educational grants from AbbVie Inc.; Janssen Pharmaceuticals, Inc.; Salix Pharmaceuticals; Shire; Takeda Pharmaceuticals U.S.A., Inc.; and UCB, Inc. He is on the advisory boards or a consultant for AbbVie Inc.; Amgen Inc.; Celgene Corporation; Janssen Pharmaceuticals, Inc.; Miraca Laboratories; Pfizer Inc.; Seres Therapeutics; Takeda Pharmaceuticals U.S.A., Inc.; and UCB, Inc.

Dr. Clarke reports that he is on the speakers bureau for AbbVie Inc.; Janssen Pharmaceuticals, Inc.; Pfizer Inc.; and Takeda Pharmaceuticals U.S.A., Inc.

Tony Graham, MD (peer reviewer) has no disclosures to report.

Michael J. Franks, MSN, AGACNP-BC, FNP-BC (peer reviewer) has no disclosures to report.

Olga Askinazi, PhD (planning committee) has no disclosures to report.

Susan Perry (planning committee) has no disclosures to report.

Jan Perez (planning committee) has no disclosures to report.

Sharon Tordoff (planning committee) has no disclosures to report.

Disclosures were obtained from the CME Outfitters, LLC, staff: No disclosures to report.

Faculty of this CE activity may include discussions of products or devices that are not currently labeled for use by the FDA. The faculty have been informed of their responsibility to disclose to the audience if they will be discussing off-label or investigational uses (any uses not approved by the FDA) of products or devices.

Additional Formats

Post-tests, credit request forms, and activity evaluations must be completed online (requires free account activation), and participants can print their certificate or statement of credit immediately (75% pass rate required). This website supports all browsers except Internet Explorer for Mac. For complete technical requirements and privacy policy, visit our Privacy & Confidentiality page.

NOTE: Pharmacist CE Universal Activity Number, Enduring: 0376-0000-21-007-H01-P

 

Questions about this activity?

Call us at (877) CME-PROS or (877) 263-7767.

 

 

PD-040-022521-90

The Role of Race in Health Care Delivery in IBD
Event Date: 01/25/2021